RSS | Login | Register

ACIPHEX

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare ACIPHEX to:

Generic Name for ACIPHEX

Rabeprazole sodium 20mg; delayed-release, e-c tabs.

Legal Classification:

Pharmacological Class for ACIPHEX

Proton pump inhibitor.

Manufacturer of ACIPHEX

PriCara

Indications for ACIPHEX

Triple therapy (w. amoxicillin + clarithromycin) for H. pylori eradication in duodenal ulcer disease. Short-term treatment of erosive or ulcerative gastroesophageal reflux disease (GERD) or duodenal ulcers. Treatment of symptomatic GERD in patients ≥12 years of age. Maintenance of healing and reduction in relapse rates of heartburn symptoms in erosive or ulcerative GERD. Long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Adult dose for ACIPHEX

Swallow whole. ≥18 years: Triple therapy: rabeprazole 20mg + amoxicillin 1g + clarithromycin 500mg, all twice daily (w. AM and PM meals) for 7 days. GERD healing: 20mg once daily for 4–8 weeks; may repeat for 8 more weeks. GERD symptoms: 20mg once daily for 4 weeks; may repeat for 4 more weeks. GERD maintenance: 20mg once daily. Duodenal ulcer healing: 20mg once daily after breakfast for up to 4 weeks. Hypersecretory conditions: initially 60mg once daily; titrate; doses up to 100mg once daily or 60mg twice daily have been used.

Children's dosing for ACIPHEX

<12 years: not recommended. ≥12 years: Short-term treatment of GERD: 20mg once daily for up to 8 weeks.

Warnings/Precautions for ACIPHEX

Severe hepatic impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for ACIPHEX

May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, digoxin). May give antacids concomitantly. May antagonize atazanavir (not recommended). Monitor warfarin, cyclosporine.

Adverse Reactions for ACIPHEX

Headache, pain, pharyngitis, flatulence, infection, constipation. Children: also nausea.

Notes for ACIPHEX

See Amoxil entry for more information on amoxicillin. See Biaxin entry for more information on clarithromycin.

How is ACIPHEX supplied?

Tabs—30, 90

Related Disease:

Duodenal ulcers {DU}

GERD {GERD}

Hypersecretory conditions~Zollinger-Ellison syndrome

Ulcers, duodenal

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.